ReviewNature2015
Pharmacogenomics in the clinic.
Review in Nature, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 433 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
433 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- A PRISMA-guided systematic review of pharmacogenetic anticancer clinical trials registered on clinicaltrials.gov.Medicine · 2026Pooled it
- Anticholinergic Medication Burden Scales: A Systematic Review.Journal of the American Geriatrics Society · 2026Pooled it
- Vietnamese pharmacogenomic variation in global context: a systematic review and meta-analysis for clinical implementation.Frontiers in pharmacology · 2026Pooled it
- A systematic review of dexmedetomidine pharmacology in pediatric patients.Clinical and translational science · 2024Pooled it
- Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.Pharmacogenomics · 2023Pooled it
- Individualized interventions and precision health: Lessons learned from a systematic review and implications for analytics-driven geriatric research.Journal of the American Geriatrics Society · 2023Pooled it
- Pooled it
- Understanding the barriers and enablers of pharmacogenomic testing in primary care: a qualitative systematic review with meta-aggregation synthesis.Pharmacogenomics · 2022Pooled it
- Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application.The pharmacogenomics journal · 2021Pooled it
- A randomized trial to evaluate attitudes regarding pharmacogenomics among pregnant and pediatric populations: design and baseline characteristics.The pharmacogenomics journal · 2026Trial
- Bridging the pharmacogenomics gap: a survey of healthcare workers in South-Western Nigeria.The pharmacogenomics journal · 2026Article
- Operationalizing Precision Medicine in Drug Development: Predictive Biomarkers, Companion Diagnostics, and Regulatory Pathways.Clinical pharmacology and therapeutics · 2026Review
- Review
- Re: Clinical implementation of polygenic risk scores - equity metrics are needed before clinical translation.European journal of human genetics : EJHG · 2026Article
- Financing and health system capacity for precision medicine in Asia: a six country landscape analysis.Health affairs scholar · 2026Review
- Individualized pharmacotherapy: background and development.Annals of translational medicine · 2026Review
- Multi-omics-driven precision medicine.iMeta · 2026Review
- Review
- Pharmacogenetic Predictors of Chemotherapy Treatment-Related Toxicities in Paediatric and Adolescent Acute Lymphoblastic Leukemia: A Systematic Review, Meta-Analysis and Literature-Based Candidate Prioritization.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Design and implementation of PharMe: a mobile application to return pharmacogenomic test results to patients.JAMIA open · 2026Article
373 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
After decades of discovery, inherited variations have been identified in approximately 20 genes that affect about 80 medications and are actionable in the clinic. And some somatically acquired genetic variants direct the choice of 'targeted' anticancer drugs for individual patients. Current efforts that focus on the processes required to appropriately act on pharmacogenomic variability in the clinic are moving away from discovery and towards implementation of an evidenced-based strategy for improving the use of medications, thereby providing a cornerstone for precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.